Cited by 136Vitamin D Research StudiesCutaneous Melanoma Detection and Managementmelanin and skin pigmentation

Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management

Open access
Slominski, Andrzej T, Brożyna, Anna A, Zmijewski, Michal A, Jóźwicki, Wojciech, Jetten, Anton M, Mason, Rebecca S, Tuckey, Robert C, Elmets, Craig A·2017·Laboratory Investigation

Abstract

Ultraviolet B (UVB), in addition to having carcinogenic activity, is required for the production of vitamin D3 (D3) in the skin which supplies >90% of the body's requirement. Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1α-hydroxylase (CYP27B1) to produce 1,25(OH)2 D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. The active forms of D3, in addition to regulating calcium metabolism, exert pleiotropic activities, which include anticarcinogenic and anti-melanoma effects in experimental models, with photoprotection against UVB-induced damage. These diverse effects are mediated through an interaction with the vitamin D receptor (VDR) and/or as most recently demonstrated through action on retinoic acid orphan receptors (ROR)α and RORγ. With respect to melanoma, low levels of 25(OH)D are associated with thicker tumors and reduced patient survival. Furthermore, single-nucleotide polymorphisms of VDR and the vitamin D-binding protein (VDP) genes affect melanomagenesis or disease outcome. Clinicopathological analyses have shown positive correlation between low or undetectable expression of VDR and/or CYP27B1 in melanoma with tumor progression and shorter overall (OS) and disease-free survival (DFS) times. Paradoxically, this correlation was reversed for CYP24A1 (inactivating 24-hydroxylase), indicating that this enzyme, while inactivating 1,25(OH)2 D3, can activate other forms of D3 that are products of the non-canonical pathway initiated by CYP11A1. An inverse correlation has been found between the levels of RORα and RORγ expression and melanoma progression and disease outcome. Therefore, we propose that defects in vitamin D signaling including D3 activation/inactivation, and the expression and activity of the corresponding receptors, affect melanoma progression and the outcome of the disease. The existence of multiple bioactive forms of D3 and alternative receptors affecting the behavior of melanoma should be taken into consideration when applying vitamin D management for melanoma therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/labinvest.2017.3

Cites

301 of 302 references verified1 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CYP11A1 initiates novel pathways of vitamin D3 activation in various organs or tissues, such as skin, peripheral tissue, adrenals, placenta, gastrointestinal tract, and several cancer cells of different origin.

    “CYP11A1 initiates novel pathways of vitamin D3 activation in various organs or tissue, such as skin, peripheral tissue, adrenals, placenta, gastrointestinal (GI) tract, and several cancer cells of different origin [23,[27], [28], [29], [30], [31], [32], [33]].”
  • 1α,25(OH)2D3 inhibits malignant transformation and tumor progression and has anti-cancer effects on gastrointestinal, genitourinary, breast, prostate, lung, and melanoma tumors.

    “It also inhibits malignant transformation, tumor progression and has anti-cancer properties on a variety of tumors including those of gastrointestinal, genitourinary, breast, prostate and lung origins [32, 33, 46, 51], as well as melanoma [52, 53].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

9 of the 311 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [238]Slominski A Kim TK Zmijewski MA Novel vitamin D photoproducts and their precursors in the skin Dermatoendocrinol 2013 5 7 19 24494038 PMC3897599
  2. [267]Tuckey RC Li W Shehabi HZ Production of 22-hydroxy-metabolites of vitamin D3 by cytochrome P450scc (CYP11A1) and analysis of their biological activities on skin cells Drug Metab Dispos 2011 39 1577 88 21677063 PMC3164270
  3. [269]Slominski A Janjetovic Z Kim TK Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes Anticancer Res 2012 32 3733 3742 22993313 PMC3458587
  4. [281]Zmijewski MA Li W Zjawiony JK Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives Photochem Photobiol Sci 2008 7 1570 1576 19037511 PMC2597640

Cited by

Sorted by citations

Authors
Slominski, A. T., Brożyna, A. A., Zmijewski, M. A., Jóźwicki, W., Jetten, A. M., Mason, R. S., Tuckey, R. C., & Elmets, C. A.
Affiliations
  • University of Alabama at Birmingham (US)
  • Nicolaus Copernicus University (PL)
  • Gdańsk Medical University (PL)
  • National Institutes of Health (US)
  • The University of Sydney (AU)
  • The University of Western Australia (AU)
Corresponding author
Slominski, Andrzej T
Venue
Laboratory Investigation
Publisher
Elsevier BV
Published
2017-06
Volume
97
Issue
6
Pages
706-724
ISSN
0023-6837 (ISSN-L)
OpenAlex
W2589902824
Cited by
136
References
311
Citations by year
2026: 3 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 18 · 2021: 15 · 2020: 24 · 2019: 16 · 2018: 12 · 2017: 8
FWCI
2.62
Type
journal article
Language
en
Open access
Locations
  • Laboratory Investigation (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (acceptedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01BX003395)
  • Narodowym Centrum Nauki
  • National Institutes of Health (Z01-ES-101586)
  • National Health and Medical Research Council (1070688)
  • National Cancer Institute (R01CA193885)
  • National Institute of Environmental Health Sciences (Z01ES101586)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR066505, R01AR052190, R01AR056666)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Vitamin D Research Studies
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
Keywords
vitamin D signaling, melanoma, vitamin D receptor, vitamin D binding protein, CYP27B1, CYP24A1, CYP27A1, CYP2R1, CYP11A1, 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D, UV-B radiation, melanoma progression, survival outcomes, single nucleotide polymorphisms, photoprotection
MeSH terms
Animals, Cytochrome P-450 Enzyme System, Epidermis, Humans, Melanoma, Ultraviolet Rays, Vitamin D, Signal Transduction, Receptors, Calcitriol, Disease Progression, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review